Egalet Corporation (NASDAQ: EGLT) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Egalet Corporation to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Egalet Corporation and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Egalet Corporation $22.53 million -$79.77 million -0.32
Egalet Corporation Competitors $473.33 million $171.79 million -7.11

Egalet Corporation’s rivals have higher revenue and earnings than Egalet Corporation. Egalet Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Egalet Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Egalet Corporation -444.50% -607.49% -79.76%
Egalet Corporation Competitors -4,889.02% -365.40% -42.53%

Risk & Volatility

Egalet Corporation has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Egalet Corporation’s rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Egalet Corporation and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Egalet Corporation 0 0 5 0 3.00
Egalet Corporation Competitors 1412 4547 12441 314 2.62

Egalet Corporation presently has a consensus target price of $7.10, indicating a potential upside of 450.39%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 29.14%. Given Egalet Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Egalet Corporation is more favorable than its rivals.

Institutional and Insider Ownership

32.6% of Egalet Corporation shares are held by institutional investors. Comparatively, 51.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.8% of Egalet Corporation shares are held by insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Egalet Corporation rivals beat Egalet Corporation on 8 of the 12 factors compared.

About Egalet Corporation

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.